Events

The National Cancer Institute's Small Business Innovation Research (SBIR) Development Center provides funding, networking, and mentoring assistance to small businesses with early-stage innovative cancer technology projects. NCI SBIR Team Leader […]

Please save the date for this exciting conference and stay tuned for speaker updates.  James Inglese, NIH/NCATS is confirmed. More information can be found on the conference website.

Drug discovery research in Africa has lagged that carried out in the more developed nations of the world. Africa is often described as the “next frontier” in the global economy, […]

ResMed is a week-long graduate/professional-level course providing an accelerated program for medicinal chemists, biologists and other industrial and academic scientists who choose to broaden their knowledge of the drug discovery and […]

Please plan to join us for the first of our new monthly program focused on drug development topics and resources.  This interactive series kickoff will be focused on the importance […]

Keynote Speaker – Roy S. Herbst, MD. PhD, Chief of Medical Oncology and Associate Director for Translational Research, Yale Cancer CenterSpeakers Include: Yannick Bulliard, Immatics; Eric Chang, BCM; Diana Chow, Univ […]

Confirmed speakers include Lisa Marcaurelle, Director of Chemistry at GlaxoSmithKline and Damian Young, Baylor College of Medicine.  When you register, you will have the opportunity to submit questions that you would like […]

We invite you to join us for the December Roundtable Workshop which will highlight the use of computational approaches for drug discovery and lead optimization.  Additionally, you will learn about […]

Drs. Ross Chambers (Integral Molecular) and Zhiqiang An (UTHealth) will speak on Overcoming the challenges of antibody discovery against multipass membrane proteins, and Antibody Drug Discovery: Challenges and Opportunities, respectively.

Drs. Andy Phillips (C4 Therapeutics) and Michael “Mick” Soth (MD Anderson IACS) will speak on Targeted Protein Degradation and Targeting Glutaminase Addition in Cancer: Development of a GLS1 Inhibitor, respectively.  […]